Evidence map›Paper›PMID 35119359›Full record

ArticleeLife2022

Novel insights from a multiomics dissection of the Hayflick limit.

Michelle Chan, Han Yuan, Ilya Soifer, Tobias M Maile, Rebecca Y Wang, Andrea Ireland, Jonathon J O'Brien, Jérôme Goudeau, Leanne J G Chan, Twaritha Vijay and 10 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. AcutebioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Michelle ChanCalico Life Sciences, LLC, South San Francisco, United States.
Han Yuan *Calico Life Sciences, LLC, South San Francisco, United States.
Ilya Soifer *Calico Life Sciences, LLC, South San Francisco, United States.
Tobias M MaileCalico Life Sciences, LLC, South San Francisco, United States.
Rebecca Y WangCalico Life Sciences, LLC, South San Francisco, United States.
Andrea IrelandCalico Life Sciences, LLC, South San Francisco, United States.
Jonathon J O'BrienCalico Life Sciences, LLC, South San Francisco, United States.ORCID 0000-0001-9660-4797
Jérôme GoudeauCalico Life Sciences, LLC, South San Francisco, United States.ORCID 0000-0002-2483-1955
Leanne J G ChanCalico Life Sciences, LLC, South San Francisco, United States.
Twaritha VijayCalico Life Sciences, LLC, South San Francisco, United States.
Adam FreundCalico Life Sciences, LLC, South San Francisco, United States.ORCID 0000-0002-7956-5332
Cynthia KenyonCalico Life Sciences, LLC, South San Francisco, United States.ORCID 0000-0003-3446-2636
Bryson D BennettCalico Life Sciences, LLC, South San Francisco, United States.
Fiona E McAllisterCalico Life Sciences, LLC, South San Francisco, United States.
David R KelleyCalico Life Sciences, LLC, South San Francisco, United States.
Margaret RoyCalico Life Sciences, LLC, South San Francisco, United States.
Robert L CohenCalico Life Sciences, LLC, South San Francisco, United States.
Arthur D LevinsonCalico Life Sciences, LLC, South San Francisco, United States.
David BotsteinCalico Life Sciences, LLC, South San Francisco, United States.ORCID 0000-0001-9499-4883
David G HendricksonCalico Life Sciences, LLC, South San Francisco, United States.ORCID 0000-0002-1884-5234

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The process wherein dividing cells exhaust proliferative capacity and enter into replicative senescence has become a prominent model for cellular aging in vitro. Despite decades of study, this cellular state is not fully understood in culture and even much less so during aging. Here, we revisit Leonard Hayflick's original observation of replicative senescence in WI-38 human lung fibroblasts equipped with a battery of modern techniques including RNA-seq, single-cell RNA-seq, proteomics, metabolomics, and ATAC-seq. We find evidence that the transition to a senescent state manifests early, increases gradually, and corresponds to a concomitant global increase in DNA accessibility in nucleolar and lamin associated domains. Furthermore, we demonstrate that senescent WI-38 cells acquire a striking resemblance to myofibroblasts in a process similar to the epithelial to mesenchymal transition (EMT) that is regulated by t YAP1/TEAD1 and TGF-β2. Lastly, we show that verteporfin inhibition of YAP1/TEAD1 activity in aged WI-38 cells robustly attenuates this gene expression program.

Indexed as

Cellular SenescenceEpithelial-Mesenchymal TransitionAgedAgingCell LineFibroblastsHumanschromosomesepithelial to mesenchymal transitiongene expressiongeneticsgenomicshumanmyofibroblastreplicative senescence

Identifiers

PMID35119359
PMCPMC8933007
OpenAlexW4210377729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.